Compare Firy Inc. (FIRY) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Firy Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? Firy Inc. trades at $11.73 (market cap $196.97M), while State Street SPDR S&P Biotech ETF trades at $149.82 (market cap $10.08B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 51.2× Firy Inc.'s market cap, and Firy Inc. is trading nearer its 52-week high, State Street SPDR S&P Biotech ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Firy Inc. for 13 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| FIRY | XBI | |
|---|---|---|
Market Cap | $196.97M | $10.08B |
Volume | 155,239 | 9,534,635 |
Sector | Technology | Broad Market / Factor |
52-Week High | $13.10 | $169.55 |
52-Week Low | $2.28 | $104.99 |
Typical Hold Time | 13 Days | 37 Days |
Enterprise Value | $165.57M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIRY (formerly Skillz Inc.) trades at $11.85, down 5.05% today, showing continued volatility amid its transition to a holding company structure. The stock maintains a bullish technical signal despite negative profitability metrics, with revenue stabilizing around $100M annually but net losses persisting. Recent developments include a $719M legal victory against Papaya Gaming and board additions, though cash burn remains elevated at -$86M in 2025.
The outlook remains speculative with significant execution risk. While the legal win provides potential upside, persistent losses and cash burn challenge near-term viability. Analyst consensus is cautious with 60% hold ratings, reflecting uncertainty around the company's ability to monetize assets and achieve profitability.
XBI trades at $150.23, down 0.44% on the day, with bearish technical signals dominating. The ETF faces resistance near $152-154 while finding support at $147-149 levels. Analyst coverage remains limited with a single hold rating, though recent news highlights biotech sector optimism from M&A activity and cancer vaccine breakthroughs. The fund's 0.35% expense ratio compares unfavorably to broader healthcare ETFs but offers targeted biotech exposure.
Outlook remains mixed with technical weakness offset by sector catalysts. The biotech focus provides growth potential but carries higher volatility than diversified healthcare alternatives. Key risks include sector-specific regulatory pressures and the fund's expense structure, while opportunities exist from ongoing pharmaceutical innovation and capital market improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Firy Inc.
Firy Inc. operates a mobile gaming platform in the United States, Israel, China, Malta, Hong Kong, Cyprus, and other international markets. The company operates through two segments: Skillz and RZR. Its Skillz platform enables game developers to monetize their content by integrating real-money tournaments, virtual prizes, and social competition features directly into multiplayer games.
Read more on FIRY →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
